Otsuka Corporation (TYO:4768)
Japan
· Delayed Price · Currency is JPY 3,158.00
-22.00 (-0.69%)
At close: Dec 5, 2025
Otsuka Revenue
Otsuka had revenue of 310.59B JPY in the quarter ending September 30, 2025, with 22.99% growth. This brings the company's revenue in the last twelve months to 1.29T, up 21.85% year-over-year. In the year 2024, Otsuka had annual revenue of 1.11T with 13.33% growth.
Revenue (ttm)
1,291.13B
Revenue Growth
+21.85%
P/S Ratio
0.93
Revenue / Employee
133.38M
Employees
9,680
Market Cap
1,197.52B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,107.67B | 130.30B | 13.33% |
| Dec 31, 2023 | 977.37B | 116.35B | 13.51% |
| Dec 31, 2022 | 861.02B | 9.13B | 1.07% |
| Dec 31, 2021 | 851.89B | 15.57B | 1.86% |
| Dec 31, 2020 | 836.32B | -50.21B | -5.66% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sony Group | 13.15T |
| Advantest | 977.23B |
| Tokyo Electron | 2,489.61B |
| Nintendo | 1,741.19B |
| Keyence | 1,088.90B |
| NEC Corporation | 3,506.53B |
| Fujitsu | 3,419.98B |
| Murata Manufacturing | 1,762.65B |
Otsuka News
- 9 days ago - FDA Approves Otsuka's (OTSKF) Voyxact for IgAN Treatment - GuruFocus
- 9 days ago - Otsuka gains FDA approval for sibeprenlimab for proteinuria reduction - Seeking Alpha
- 10 days ago - FDA Grants Accelerated Approval For Otsuka's VOYXACT In IgAN - Nasdaq
- 5 weeks ago - Otsuka 9-month Profit Rises; Revenue Up 5.1% - Nasdaq
- 5 months ago - Otsuka’s PTSD therapy draws efficacy concerns at FDA ahead of AdCom meeting - Seeking Alpha
- 5 months ago - SeaStar Medical's QUELIMMUNE Wins Prestigious Award From The National Kidney Foundation, Former Winners Include Names Like Janssen, Merck and Otsuka - Benzinga
- 6 months ago - Vera plunges as Otsuka outperforms with IgA nephropathy therapy - Seeking Alpha
- 6 months ago - Otsuka Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) - Benzinga